FREE ISSUE

December 2010

Volume 9Issue 12p801-826
Terpenes in Urolithiasis
September 2010
Edited byThomas Knoll
Cover images, from left to right: Survival distribution functions of the intent-to-treat population; time to stone-free status. Magenta line: placebo; orange line: the terpene combination group (log-rank-test; p = 0.0061). See article Improving Stone Clearance After Extracorporeal Shock Wave Lithotripsy in Urolithiasis Patients by a Special Terpene Combination (Rowatinex®): Results of a Placebo-Controlled, Randomized Trial in this supplement. Kidney stone crystals, coloured scanning electron micrograph. © Steve Gschmeissner / Science Photo Library. Microcalcifications on renal papilla that are thought to be precursors of calcium oxalate stones (Randall plaques). See article Epidemiology, Pathogenesis and Pathophysiology of Urolithiasis in this supplement....
Cover images, from left to right: Survival distribution functions of the intent-to-treat population; time to stone-free status. Magenta line: placebo; orange line: the terpene combination group (log-rank-test; p = 0.0061). See article Improving Stone Clearance After Extracorporeal Shock Wave Lithotripsy in Urolithiasis Patients by a Special Terpene Combination (Rowatinex®): Results of a Placebo-Controlled, Randomized Trial in this supplement. Kidney stone crystals, coloured scanning electron micrograph. © Steve Gschmeissner / Science Photo Library. Microcalcifications on renal papilla that are thought to be precursors of calcium oxalate stones (Randall plaques). See article Epidemiology, Pathogenesis and Pathophysiology of Urolithiasis in this supplement.

Editorial Board

Contents list

Editorial

Review article

Full length article

Advertisement